Accuray (ARAY)
(Delayed Data from NSDQ)
$1.78 USD
-0.03 (-1.66%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.78 USD
-0.03 (-1.66%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth D Momentum B VGM
Zacks News
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.
Why Is Accuray (ARAY) Down 28.2% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Avanos (AVNS) gains from segmental contributions in Q4.
OPKO Health (OPK) Q4 Loss Narrower Than Estimates, Sales Up
by Zacks Equity Research
OPKO (OPK) gains from increase in RAYALDEE prescriptions.
LHC Group (LHCG) Q4 Earnings Meet Estimates, Revenues Lag
by Zacks Equity Research
LHC Group (LHCG) fourth-quarter results benefit from home health and hospice admissions and higher revenues.
Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results benefit from higher revenues and solid show by Dental as well as Animal Health segments.
Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Nevro (NVRO) sees strong segmental contributions in Q4.
Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.
Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
Inogen (INGN) sees segmental softness in the fourth quarter.
Penumbra (PEN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Penumbra (PEN) registers balanced segmental growth across all geographies in Q4.
Merit Medical (MMSI) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical's (MMSI) fourth-quarter results gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.
PRA Health (PRAH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Solid Clinical Research revenues drove PRA Health's (PRAH) Q4 results.
HMS Holdings (HMSY) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HMS Holdings' (HMSY) fourth-quarter earnings benefit from higher revenues at Analytical Services unit and strong 2020 outlook.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.
Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.
Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive
by Zacks Equity Research
Masimo (MASI) sees expansion in gross and operating margin in Q4.
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.
Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) registers solid performance by each of its key operating businesses in Q4.
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.
Medtronic (MDT) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Medtronic (MDT) demonstrates better-than-expected Q3 performances at CER, backed by growth in all major business segments and geographies.
Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks
by Nalak Das
President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.
Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.
DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.